Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: When, where, and how to use?

Current Opinion in Infectious Diseases

Volumn 29, Issue 1, 2016, Pages 45-51

  Low, Nicola ^a   Unemo, Magnus ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Örebro University   (Sweden)

Author keywords

Antimicrobial resistance; Antimicrobial surveillance; Neisseria gonorrhoeae; Point of care tests

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM DETECTION; CROSS REACTION; GONORRHEA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DIAGNOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PATIENT CARE; POINT OF CARE TESTING; REVIEW; BACTERIUM IDENTIFICATION; DEVICES; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MOLECULAR EPIDEMIOLOGY; POINT OF CARE SYSTEM; PROCEDURES; TRENDS;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; NEISSERIA GONORRHOEAE; POINT-OF-CARE SYSTEMS;

EID: 84952719585     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000230     Document Type: Review

References (55)

1. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: World Health Organization; 2012.
2. Laxminarayan R. Antibiotic effectiveness: balancing conservation against innovation. Science 2014; 345:1299-1301.
3. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/CSR/2001.3. Geneva: 2001. pp. 1-58.
4. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014; 27:587-613.
5. Lewis DA, Sriruttan C, Muller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporinresistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemotherapy 2013; 68:1267-1270.
6. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drugresistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401-1422.
7. Allen VG, Farrell DJ, Rebbapragada A, et al. Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 2011; 55:703-712.
8. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538-3545.
9. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxoneresistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-1280.
10. Unemo M. Current and future antimicrobial treatment of gonorrhoea: the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 2015; 15:364.
11. Low N, Unemo M, Skov Jensen J, et al. Molecular diagnostics for gonorrhoea: implications for antimicrobial resistance and the threat of untreatable gonorrhoea. PLoS Med 2014; 11:e1001598.
12. Bignell C, Unemo M. 2012 European Guideline on the diagnosis and treatment of gonorrhoea. Int J STD AIDS 2013; 24:85-92.
13. Dicker LW, Mosure DJ, Steece R, Stone KM. Laboratory tests used in US public health laboratories for sexually transmitted diseases, 2004. Sex Transm Dis 2007; 34:41-46.
14. Goire N, Lahra MM, Chen M, et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol 2014; 12:223-229.
15. Buono SA, Watson TD, Borenstein LA, et al. Stemming the tide of drugresistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. J Antimicrob Chemother 2015; 70:374-381.
16. Lewis DA. Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Curr Opin Infect Dis 2014; 27:62-67.
17. Peterson SW, Martin I, Demczuk W, et al. Molecular assay for detection of genetic markers associated with decreased susceptibility to cephalosporins in Neisseria gonorrhoeae. J Clin Microbiol 2015; 53:2042-2048.
18. Peterson SW, Martin I, Demczuk W, et al. Molecular assay for the detection of ciprofloxacin resistance in Neisseria gonorrhoeae from cultures and clinical Nucleic Acid Amplification Test (NAAT) specimens. J Clin Microbiol 2015; 53:3606-3608.
19. Buckley C, Trembizki E, Baird RW, et al. Multitarget PCR assay for direct detection of penicillinase-producing Neisseria gonorrhoeae for enhanced surveillance of gonococcal antimicrobial resistance. J Clin Microbiol 2015; 53:2706-2708.
20. Lawung R, Cherdtrakulkiat R, Charoenwatanachokchai A, et al. Antimicrobial resistance markers as a monitoring index of gonorrhoea in Thailand. Acta Microbiol Immunol Hung 2012; 59:157-169.
21. Trembizki E, Buckley C, Donovan B, et al. Direct real-time PCR-based detection of Neisseria gonorrhoeae 23S rRNA mutations associated with azithromycin resistance. J Antimicrob Chemother 2015. [Epub ahead of print]
22. Fayemiwo SA, Muller EE, Gumede L, Lewis DA. Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011; 38:329-333.
23. Gose S, Nguyen D, Lowenberg D, et al. Neisseria gonorrhoeae and extendedspectrum cephalosporins in California: surveillance and molecular detection of mosaic penA. BMC Infect Dis 2013; 13:570.
24. Goire N, Lahra MM, Ohnishi M, et al. Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain. Euro Surveill 2013; 18:20444.
25. Ochiai S, Ishiko H, Yasuda M, Deguchi T. Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol 2008; 46:1804-1810.
26. Nicol M, Whiley D, Nulsen M, Bromhead C. Direct detection of markers associated with Neisseria gonorrhoeae antimicrobial resistance in New Zealand using residual DNA from the Cobas 4800 CT/NG NAAT assay. Sex Transm Infect 2014; 91:91-93.
27. Balashov S, Mordechai E, Adelson ME, Gygax SE. Multiplex bead suspension array for screening Neisseria gonorrhoeae antibiotic resistance genetic determinants in noncultured clinical samples. J Mol Diagn 2013; 15:116-129.
28. Lawung R, Cherdtrakulkiat R, Charoenwatanachokchai A, et al. One-step PCR for the identification of multiple antimicrobial resistance in Neisseria gonorrhoeae. J Microbiol Meth 2009; 77:323-325.
29. Goire N, Ohnishi M, Limnios AE, et al. Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain. J Antimicrob Chemother 2012; 67:902-905.
30. Goire N, Freeman K, Tapsall JW, et al. Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinaseproducing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol 2011; 49:513-518.
31. Siedner MJ, Pandori M, Castro L, et al. Real-time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples. J Clin Microbiol 2007; 45:1250-1254.
32. Magooa MP, Muller EE, Gumede L, Lewis DA. Determination of Neisseria gonorrhoeae susceptibility to ciprofloxacin in clinical specimens from men using a real-time PCR assay. Int J Antimicrob Agents 2013; 42:63-67.
33. Li Z, Yokoi S, Kawamura Y, et al. Rapid detection of quinolone resistanceassociated gyrA mutations in Neisseria gonorrhoeae with a LightCycler. J Infect Chemother 2002; 8:145-150.
34. Zhou W, Du W, Cao H, et al. Detection of gyrA and parC mutations associated with ciprofloxacin resistance in Neisseria gonorrhoeae by use of oligonucleotide biochip technology. J Clin Microbiol 2004; 42:5819-5824.
35. Zhao L, Zhao S. TaqMan real-time quantitative PCR assay for detection of fluoroquinolone-resistant Neisseria gonorrhoeae. Curr Microbiol 2012; 65:692-695.
36. Dona V, Low N, Guilarte YN, et al. Multiplex real-time PCR with high resolution melting analysis for detecting resistance mechanisms in Neisseria gonorrhoeae. Oral Presentation O05.3. World STI & HIV Congress 2015. Brisbane, Australia, 13-16 September 2015. Sex Transm Infect 2015; 91(Suppl 2): A35-A36.
37. Hemarajata P, Yang S, Soge OO, et al. Real-time PCR and melt curve analysis targeting gyrA gene for prediction of ciprofloxacin resistance in clinical Neisseria gonorrhoeae isolates. Oral Presentation O05.1. World STI & HIV Congress. Brisbane, Australia, 13-16 September 2015. Sex Transm Infect 2015; 91(Suppl 2):A35.
38. Pond MJ, Hall C, Cole M, et al. Diagnostic and clinical implications of genotypic fluoroquinolone susceptibility detection for Neisseria gonorrhoeae. Oral presentation O05.2.World STI & HIV Congress 2015. Brisbane, Australia, 13-16 September 2015. Sex Transm Infect 2015; 91 (Suppl 2):A35.
39. British Association of Sexual Health and HIV Clinical Effectiveness Group. Bignell C, Ison C, FitzGerald M. United Kingdom national guideline for gonorrhoea testing 2012. London: British Association of Sexual Health and HIV; 2012.
40. Okeke IN, Peeling RW, Goossens H, et al. Diagnostics as essential tools for containing antibacterial resistance. Drug Resist Updat 2011; 14:95-106.
41. Cole M, Spiteri G, Chisholm S, et al. Emerging cephalosporin and multidrugresistant gonorrhoea in Europe. Euro Surveill 2014; 19:20955.
42. Public Health England. GRASP 2013 Report. The Gonococcal Resistance to Antimicrobials Surveillance Programme (England and Wales). London: 2014; Public Health England.
43. Kirkcaldy RD, Kidd S, Weinstock HS, et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013; 89 (Suppl 4):iv5-iv10.
44. Speers DJ, Fisk RE, Goire N, Mak DB. Nonculture Neisseria gonorrhoeae molecular penicillinase production surveillance demonstrates the long-term success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. J Antimicrob Chemother 2014; 69:1243-1247.
45. Ng LK, Martin I, Liu G, Bryden L. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002; 46:3020-3025.
46. Yang Y, Liao M, Gu WM, et al. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother 2006; 58:868-872.
47. Pai NP, Vadnais C, Denkinger C, et al. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low-and middle-income countries. PLoS Med 2012; 9:e1001306.
48. NESTA. Longitude Prize. https://longitudeprize.org/. London: 2014. [Accessed 19 October 2015]
49. Gaydos CA. Review of use of a new rapid real-time PCR, the Cepheid GeneXpert(R) (Xpert) CT/NG assay, for Chlamydia trachomatis and Neisseria gonorrhoeae: results for patients while in a clinical setting. Exp Rev Mol Diagn 2014; 14:135-137.
50. Kugelman G, Tapsall JW, Goire N, et al. Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR green-based real-time PCR. Antimicrob Agents Chemother 2009; 53:4211-4216.
51. Chin CD, Laksanasopin T, Cheung YK, et al. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat Med 2011; 17:1015-1019.
52. Peeling RW, Smith PG, Bossuyt PM. A guide for diagnostic evaluations. Nat Rev Microbiol 2008; 6:S2-S6.
53. Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53:4032-4034.
54. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010; 54:3812-3816.
55. Jerse AE, Bash MC, Russell MW. Vaccines against gonorrhea: current status and future challenges. Vaccine 2014; 32:1579-1587.